Suppliers in Houston, TX
487 Medicare Suppliers found. Showing 101 - 120
 Cvs Pharmacy #07038 Durable Medical Equipment & Medical Supplies Location: 6504 W Little York Rd, Houston, Texas 77040 Phone: (713) 937-9600 |
|
|
|
|
Cvs Pharmacy #07198 Pharmacy Location: 3811 Old Spanish Trl, Houston, Texas 77021 Phone: (713) 741-7900 |
Cvs Pharmacy #07222 Pharmacy Location: 4131 Aldine Mail Route, Houston, Texas 77039 Phone: (281) 985-4741 |
|
Cvs Pharmacy #07286 Durable Medical Equipment & Medical Supplies Location: 2469 Bay Area Blvd, Houston, Texas 77058 Phone: (281) 486-0613 |
|
|
|
|
|
Cvs Pharmacy #08912 Durable Medical Equipment & Medical Supplies Location: 1002 Gessner Dr, Houston, Texas 77055 Phone: (713) 647-0259 |
Cvs Pharmacy #10178 Durable Medical Equipment & Medical Supplies Location: 10200 Cullen Blvd, Houston, Texas 77047 Phone: (713) 731-4413 |
Cvs Pharmacy #10301 Durable Medical Equipment & Medical Supplies Location: 1525 North Loop W, Houston, Texas 77008 Phone: (713) 868-7456 |
Cvs Pharmacy #10554 Durable Medical Equipment & Medical Supplies Location: 2111 W Alabama St, Houston, Texas 77098 Phone: (713) 874-1085 |
Cvs Pharmacy #10638 Durable Medical Equipment & Medical Supplies Location: 9410 Fuqua St, Houston, Texas 77075 Phone: (713) 987-9479 |
Cvs Pharmacy #11094 Durable Medical Equipment & Medical Supplies Location: 300 Milam St, Houston, Texas 77002 Phone: (713) 223-0371 |
News Archive
Study shows how caffeine counteracts age-related cognitive deficits in animals
A study published in the journal Scientific Reports from Nature publishing group, describes the mechanism by which caffeine counteracts age-related cognitive deficits in animals.
Mefloquine shows potential as anti-SARS-CoV-2 drug
A team of scientists from Japan has identified the approved anti-material drug, mefloquine, as a potential candidate to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Specifically, mefloquine has been shown to prevent the entry of SARS-CoV-2 into host cells and reduce the viral load in vitro.
Research could help clinicians identify patients who may benefit from targeted therapy for liver cancer
New research from Roswell Park Cancer Institute offers clinicians treating patients with advanced liver cancer a way of determining which patients may benefit most from the targeted therapy sorafenib.
FDA grants Senesco's SNS01-T orphan-drug designation to treat lymphomas
Senesco Technologies, Inc. reported today that it was informed on July 26th that the U.S. Food and Drug Administration has granted orphan-drug designation for the company's lead drug candidate SNS01-T for treatment of both mantle cell lymphoma and diffuse large B-cell lymphoma.
Microencapsulated brain cancer drug may simplify treatment and provide tightly controlled therapy
Consistently uniform, easily manufactured microcapsules containing a brain cancer drug may simplify treatment and provide more tightly controlled therapy, according to Penn State researchers.
› Verified 8 days ago